influenza
major
acut
respiratori
infect
caus
mortal
morbid
worldwid
two
class
convent
antivir
ion
channel
blocker
neuraminidas
inhibitor
mainstay
manag
influenza
diseas
lessen
symptom
minim
hospit
death
patient
sever
influenza
howev
develop
viral
resist
drug
class
becom
major
public
health
concern
vaccin
prophylaxi
mainstay
limit
efficaci
due
difficulti
match
predict
domin
viral
strain
circul
strain
potenti
intervent
explor
sinc
virus
reli
host
cellular
function
replic
recent
therapeut
develop
focu
target
host
factor
involv
viru
replic
besid
control
viru
replic
potenti
target
drug
develop
includ
control
virusinduc
host
immun
respons
recent
suggest
involv
innat
lymphoid
cell
nadph
oxidas
influenza
viru
pathogenesi
immun
cell
metabol
review
discuss
advanc
novel
hostbas
intervent
treat
influenza
diseas
influenza
major
acut
respiratori
infect
caus
mortal
morbid
worldwid
two
class
convent
antivir
ion
channel
blocker
neuraminidas
inhibitor
mainstay
manag
influenza
diseas
lessen
symptom
minim
hospit
death
patient
sever
influenza
howev
develop
viral
resist
drug
class
becom
major
public
health
concern
vaccin
prophylaxi
mainstay
limit
efficaci
due
difficulti
match
predict
domin
viral
strain
circul
strain
potenti
intervent
explor
sinc
virus
reli
host
cellular
function
replic
recent
therapeut
develop
focu
target
host
factor
involv
viru
replic
besid
control
viru
replic
potenti
target
drug
develop
includ
control
virusinduc
host
immun
respons
recent
suggest
involv
innat
lymphoid
cell
nadph
oxidas
influenza
viru
pathogenesi
immun
cell
metabol
review
discuss
advanc
novel
hostbas
intervent
treat
influenza
diseas
keyword
host
factor
influenza
cytokin
metabol
immunomodul
introduct
influenza
remain
sourc
public
health
concern
influenza
viru
iav
caus
histor
noxiou
pandem
spanish
flu
asian
flu
hong
kong
flu
recent
pandem
swine
flu
influenza
also
caus
season
epidem
outbreak
high
morbid
mortal
rate
outbreak
india
errorpron
natur
viral
rna
polymeras
rdrp
viru
capac
genet
reassort
antigen
drift
shift
result
viral
compon
suscept
mutat
allow
virus
evad
immun
system
increas
resist
control
strategi
current
influenza
vaccin
two
class
antivir
ion
channel
blocker
amantadin
rimantadin
neuraminidas
na
inhibitor
oseltamivir
zanamivir
peramivir
novel
treatment
option
use
polymeras
inhibitor
favipiravir
consid
mainstay
influenza
infect
treatment
control
use
influenza
vaccin
remain
challeng
due
antigen
drift
shift
season
variat
new
circul
speci
product
vaccin
time
consum
efficaci
concern
especi
case
pandem
variat
vaccin
efficaci
caus
age
awar
studi
suggest
vaccineconf
protect
may
optim
certain
age
group
disadvantag
use
convent
antivir
drug
also
concern
signific
level
resist
class
drug
repeatedli
report
high
level
resist
blocker
report
viru
strain
american
isol
resist
also
report
viru
iav
resist
na
inhibitor
also
becom
increasingli
preval
concern
recent
highli
fatal
outbreak
influenza
india
associ
oseltamivir
drug
resist
addit
larg
cluster
influenza
virus
japan
found
increas
oseltamivir
peramivir
drug
resist
urgent
need
search
altern
target
treat
influenza
viru
infect
includ
nonvir
target
host
cellular
factor
promis
virus
reli
host
machineri
replic
host
immun
respons
intend
confer
degre
protect
infect
impair
exagger
host
immun
respons
could
detrimentaliav
viru
infect
report
exagger
aberr
cytokin
releas
result
cytokin
storm
caus
acceler
host
death
mani
recent
studi
focus
investig
target
host
factor
control
viru
replic
well
modul
immun
respons
previous
evalu
review
discuss
latest
studi
past
year
investig
novel
hostbas
approach
potenti
influenza
treatment
replic
cycl
iav
grossli
divid
four
differ
stage
entri
genom
nuclear
import
replic
protein
synthesi
genom
nuclear
export
apic
transport
assembl
bud
oblig
intracellular
pathogen
iav
heavili
depend
host
machineri
replic
propag
extent
studi
employ
genomewid
rna
interfer
rnai
screen
host
factor
involv
iav
replic
cycl
perform
increas
number
approach
target
host
factor
control
iav
replic
investig
entri
iav
host
cell
divid
sever
step
first
hemagglutinin
ha
surfac
iav
bind
termin
acid
host
cell
receptor
induc
intern
viral
particl
clathrindepend
caveolin
clathrinindepend
endocytosi
macropinocytosi
reveal
altern
entri
pathway
iav
subsequ
enter
canon
endocyt
pathway
vesiclecontain
viral
particl
form
earli
endosom
also
known
sort
endosom
matur
late
endosom
endocyt
pathway
progress
gradual
decreas
intralumin
ph
ph
mediat
vatpas
proton
pump
take
place
endosom
matur
ph
drop
endosom
lumen
induc
conform
chang
ha
activ
proteolyt
cleavag
gener
precursor
molecul
conform
chang
trigger
fusion
viral
envelop
endosom
membran
releas
viral
genom
cytoplasm
acidif
endosom
caus
subsequ
acidi
ficat
viral
lumen
via
iav
proton
channel
turn
promot
dissoci
layer
viral
envelop
viral
ribonucleoprotein
vrnp
complex
interestingli
sharp
decreas
ph
neutral
acid
ph
util
acid
bypass
observ
suboptim
viral
replic
henc
propos
gradual
decreas
endosom
ph
necessari
sequenti
reduct
viral
stiff
dissoci
np
vrnp
complex
destabil
layer
viral
envelop
eventu
conform
chang
ha
releas
viral
genom
protein
cytoplasm
late
endosom
proteolyt
cleavag
import
step
iav
replic
cleavag
reloc
convert
previous
uncleav
metast
conform
induc
membran
fusion
acid
ph
ineffici
cleavag
activ
ha
lead
low
infect
identifi
protein
encod
viral
genom
possess
proteolyt
properti
viru
depend
host
proteas
cleavag
ha
provid
potenti
target
control
iav
infect
ha
commonli
cleav
trypsinlik
proteas
singl
arginin
residu
posit
human
airway
epithelium
serin
proteas
hat
identifi
host
factor
cleavag
residu
aprotinin
purifi
bovin
lung
proteas
inhibitor
long
histori
clinic
use
antifibrinolyt
agent
cardiac
surgeri
potenti
antiiav
drug
recogn
decad
shown
reduc
infect
broad
spectrum
iav
strain
vitro
vivo
withdrawn
western
drug
market
due
associ
mortal
aprotinin
approv
local
administ
smallparticl
aerosol
drug
treatment
iav
infect
russia
howev
sideeffect
associ
system
administr
aprotinin
rais
need
altern
proteas
inhibitor
use
treatment
iav
infect
camostat
serin
proteas
inhibitor
report
demonstr
antiiav
potenti
mice
date
back
littl
research
conduct
develop
antiiav
treatment
revisit
proven
one
effici
serin
proteas
inhibitor
inhibit
iav
replic
primari
human
tracheal
epitheli
cell
vitro
test
compound
use
similar
molar
present
camostat
wide
administ
treatment
liver
fibrosi
chronic
pancreat
cancer
make
highli
promis
candid
drug
repurpos
despit
lack
associ
camostat
increas
mortal
aprotinin
report
camostat
potenti
induc
acut
eosinophil
pneumonia
warrant
need
care
consider
research
reposit
drug
class
highli
pathogen
iav
subtyp
report
ha
cleavag
site
rich
basic
residu
polybas
natur
cleavag
site
provid
multipl
target
broad
spectrum
proteas
includ
ubiquit
express
intracellular
proteas
furin
increas
proteas
spectrum
could
util
virus
activ
ha
prior
viral
bud
allow
evas
potenti
inhibit
exogen
administ
serin
proteas
inhibitor
furthermor
vivo
studi
util
mice
treat
singl
proteas
inhibitor
prior
infect
viru
bear
polybas
cleavag
site
show
poor
efficaci
despit
good
result
obtain
infect
viru
bear
singl
cleavag
site
suggest
strain
specif
use
serin
proteas
inhibitor
treat
iav
infect
endosom
acidif
requir
releas
iav
genom
form
vrnp
complex
cytoplasm
research
shown
increas
endosom
ph
earli
phase
infect
could
inhibit
iav
infect
vitro
bring
light
possibl
control
iav
infect
prevent
endosom
acidif
vatpas
inhibitor
bafilomycin
use
high
concentr
nm
proven
inhibit
iav
replic
effici
suppress
vatpas
howev
promin
cytotox
host
cell
also
observ
concentr
interestingli
lower
concentr
nm
bafilomycin
lack
inhibitori
effect
vatpas
attenu
iav
replic
due
disrupt
endosom
traffick
thu
bafilomycin
suggest
exert
antivir
function
via
distinct
mechan
differ
concentr
diphyllin
isol
plant
cleistanthu
collinu
natur
compound
abl
induc
vatpas
inhibitori
effect
contrast
bafilomycin
diphyllin
welltoler
vitro
without
induc
obviou
cytotox
effect
notabl
diphyllin
found
effect
inhibit
replic
viral
strain
resist
amantadin
andor
oseltamivir
sinc
drug
resist
wide
administ
antivir
major
public
health
concern
diphyllin
regard
promis
antivir
drugresist
iav
strain
releas
iav
genom
materi
replic
requir
fusion
endosom
membran
viral
envelop
sinc
cholesterol
play
major
role
control
fluiditi
lipid
bilay
cell
henc
suspect
role
infect
cycl
iav
interferoninduc
transmembran
protein
ifitm
protein
express
mani
vertebr
includ
human
found
plasma
membran
membran
earli
late
endosom
well
lysosom
human
express
ifitm
immunerel
well
interferon
ifn
induc
observ
restrict
replic
differ
virus
includ
iav
studi
suggest
ifitm
limit
viral
infect
reduc
membran
fluiditi
henc
restrict
hemifus
mix
lipid
bilay
without
releas
viral
content
viral
endosom
membran
probabl
via
disrupt
cholesterol
homeostasi
late
endosom
viral
fusion
genom
releas
convent
take
place
recent
studi
use
rnai
also
demonstr
cholesterol
homeostasi
regul
via
acid
phosphatas
mediat
niemannpick
activ
impair
membran
fusion
iav
influenza
b
viru
ibv
suggest
import
control
cholesterol
homeostasi
releas
viral
genom
cytoplasm
contrari
later
studi
suggest
exert
antivir
activ
cholesterolindepend
manner
show
increas
cholesterol
composit
late
endosom
membran
fail
inhibit
viral
membran
fusion
addit
studi
suggest
accumul
cholesterol
level
late
endosom
inhibit
iav
genom
releas
cytoplasm
modul
cholesterol
level
host
endosom
membran
mean
inhibit
iav
host
cell
entri
still
debat
studi
requir
clear
conclus
drawn
compar
mirna
profil
iavpermiss
hek
cell
less
permiss
hela
cell
identifi
neg
regul
iav
infect
via
inhibit
archain
also
known
subunit
copi
complex
requir
intracellular
traffick
endosom
function
deplet
report
inhibit
iav
infect
despit
impair
iav
intern
caus
deplet
via
sirna
abl
recapitul
acut
inhibit
copi
complex
pharmaceut
mean
hypothes
longterm
last
day
perturb
rnai
affect
gener
endosom
traffick
network
phenomena
recapitul
acut
pharmaceut
inhibit
block
iav
infect
potenti
target
iav
treatment
deserv
investig
despit
favor
result
rnai
studi
nuclear
import
vrnp
complex
cytoplasm
follow
fusion
viral
endosom
membran
requir
replic
take
place
earli
studi
suggest
vrnp
complex
could
transport
peripheri
nucleu
recent
studi
report
vrnp
complex
util
system
nuclear
import
lack
knockout
mous
model
found
resist
iav
infect
ivermectin
long
clinic
administ
treatment
parasitosi
recent
come
attent
potenti
inhibitor
ivermectin
inhibit
shown
inhibit
replic
rna
virus
dengu
viru
ivermectin
recent
test
inhibit
iav
vitro
nuclear
import
vrnp
complex
wildtyp
antivir
mxa
escap
mutant
effici
inhibit
given
ivermectin
longstand
record
clinic
applic
fdaapprov
statu
repurpos
drug
treatment
iav
consid
especi
threat
pandem
iav
outbreak
follow
import
vrnp
complex
nucleu
host
cell
rdrp
use
vrna
templat
synthes
mrna
crna
synthes
crna
remain
nucleu
new
vrna
gener
mrna
export
nucleu
translat
viral
protein
product
either
transport
cell
surfac
via
golgi
case
ha
na
import
back
nucleu
bind
vrna
form
new
vrnp
complex
numer
host
factor
involv
process
henc
could
possibl
target
therapeut
intervent
eight
genom
segment
iav
ns
segment
well
known
undergo
splice
gener
least
two
differ
mrna
per
individu
segment
kinas
kinas
regul
altern
splice
premrna
inhibit
chemic
knockdown
shown
caus
decreas
mrna
gener
disrupt
downstream
protein
express
promin
reduc
iav
propag
clypearin
corilagin
found
potent
antiiav
compound
higher
therapeut
index
vitro
clypearin
isol
herb
use
chines
medicin
practition
treat
respiratori
tract
diseas
replic
viral
mrna
export
nucleu
cytoplasm
protein
synthesi
take
place
human
rna
polymeras
ii
activ
found
correl
iav
replic
inhibit
nuclear
export
certain
viral
mrna
mrna
cyclosporin
csa
fdaapprov
drug
immunomodulatori
function
found
antiiav
effect
cyclophilin
cypa
depend
independ
manner
cypadepend
effect
found
correl
nuclear
export
vrnp
complex
see
target
nuclear
export
complex
cypaindepend
effect
caus
inhibit
host
rna
polymeras
ii
csa
prospect
drug
candid
treatment
iav
infect
rel
high
barrier
develop
intrins
drug
resist
oppos
commonli
use
antivir
nuclear
rna
export
factor
host
factor
identifi
involv
nuclear
export
iav
mrna
knockdown
hek
cell
reveal
promin
viral
mrna
nuclear
retent
host
cell
nucleu
protectin
endogen
produc
lipid
respiratori
tract
identifi
potent
antiinflammatori
antivir
effect
product
notabl
found
reduc
lung
iavinfect
mice
therapeut
administr
shown
significantli
reduc
iav
mrna
express
lower
lung
viral
titer
well
improv
surviv
iavinfect
mice
mechanist
studi
reveal
attenu
cytoplasm
transloc
viral
mrna
treatment
decreas
recruit
viral
transcript
observ
nuclear
export
host
rna
remain
larg
unaffect
suggest
role
regul
nuclear
export
viral
rna
natur
express
human
airway
make
ideal
candid
novel
therapeut
treatment
iav
infect
eukaryot
initi
famili
play
import
role
protein
translat
impair
proven
relat
antivir
activ
broad
spectrum
rna
virus
vitro
inhibit
iav
mrna
translat
inhibitor
silvestrol
pateamin
demonstr
arrest
viral
protein
synthesi
thu
block
viral
genom
replic
vitro
although
silvestrol
pateamin
caus
high
cytotox
concentr
requir
effect
iav
inhibit
drug
target
mrna
translat
variou
diseas
approv
fda
activ
develop
inhibit
iav
infect
disrupt
mrna
translat
may
well
therapeut
approach
futur
posttransl
modif
protein
matur
ensur
proper
function
protein
protein
iav
except
nitazoxanid
fdalicens
drug
use
treat
enter
found
effect
control
iav
infect
interf
ha
nglycosyl
well
intracellular
traffick
host
cell
eventu
led
reduct
viral
bud
despit
mechan
nitazoxanid
present
unknown
abil
inhibit
replic
numer
virus
iav
respiratori
syncyti
viru
coronaviru
hepat
b
viru
mani
other
suggest
may
act
host
machineri
drug
also
proven
vitro
inhibit
propag
mani
circul
strain
human
iav
includ
resist
oseltamivir
zanamivir
nitazoxanid
high
barrier
resist
iav
viral
strain
resist
neuraminidas
inhibitor
make
promis
therapeut
target
iav
treatment
drug
current
phase
iii
clinic
trial
later
stage
viral
replic
viral
rna
iav
pack
rdrp
np
known
vrnp
complex
export
nucleu
assembl
transport
plasma
membran
apic
polar
cell
bud
novel
target
influenza
treatment
frontier
immunolog
wwwfrontiersinorg
juli
volum
articl
exportin
also
known
well
known
function
nuclear
export
protein
rna
includ
viral
rna
similar
hiv
iav
viral
rna
directli
bind
instead
held
togeth
sever
viral
protein
viral
nuclear
export
protein
nep
previous
known
vrnp
complex
propos
nuclear
export
complex
cellular
proven
crucial
nuclear
export
vrnp
complex
earli
studi
use
leptomycin
b
lmb
potent
inhibitor
reveal
vitro
inhibit
led
nuclear
retent
vrnp
complex
howev
lmb
deem
unsuit
develop
potenti
drug
phase
clinic
trial
due
observ
cytotox
effect
verdinexor
also
known
new
bioavail
select
inhibitor
shown
effect
differ
strain
iav
vitro
vivo
prophylact
therapeut
treatment
worth
mention
delay
administr
verdinexor
day
postinfect
still
deem
benefici
reduc
viral
load
vivo
suggest
prolong
therapeut
time
window
compar
mainstay
antivir
drug
oseltamivir
recommend
administr
earli
stage
infect
within
h
symptom
onset
current
verdinexor
pass
phase
clinic
studi
trial
suggest
pose
sever
cytotox
effect
lmb
addit
recent
report
demonstr
new
drug
bind
inhibit
function
suppress
iav
replic
vitro
strengthen
concept
iav
intervent
target
viral
protein
crucial
assist
nuclear
export
vrnp
complex
commonli
suggest
protein
link
vrnp
complex
viral
nuclear
export
protein
nep
interact
nuclear
export
thu
viral
protein
may
serv
target
inhibit
nuclear
export
vrnp
previous
mention
see
inhibit
mrna
export
csa
inhibit
iav
replic
via
cypadepend
independ
mechan
recent
studi
use
transgen
mice
overexpress
cypa
show
greater
resist
iav
challeng
cypadepend
mechan
csa
enhanc
bind
cypa
protein
increas
selfassoci
hinder
nuclear
import
csa
also
promot
cypadepend
degrad
viral
protein
csa
seem
promis
drug
inhibit
nuclear
export
vrnp
complex
inhibit
viral
protein
stabil
function
recent
tetraspanin
defin
four
transmembran
domain
conserv
residu
express
abundantli
lung
interact
integrin
implic
regul
iav
replic
vitro
vivo
knockdown
primari
human
nasal
epitheli
cell
result
nuclear
retent
host
viral
np
nep
protein
increas
surviv
rate
observ
iavinfect
knockout
mice
coimmunoprecipit
assay
suggest
interact
viral
np
nep
protein
howev
exact
domain
involv
interact
mechan
function
nuclear
export
remain
unclear
given
small
molecul
inhibitor
develop
data
reveal
role
iav
infect
subsequ
use
target
antiiav
therapi
anticip
iav
infect
rafmekerk
signal
cascad
activ
inhibit
mek
probabl
mediat
via
myosin
light
chain
known
motor
protein
impair
nuclear
export
vrnp
complex
suppress
iav
replic
inhibit
rafmekerk
signal
cascad
illustr
vivo
vitro
replic
ibv
well
borna
diseas
viru
shown
inhibit
suggest
versatil
approach
control
infect
differ
virus
despit
effect
administ
local
lung
via
aerosol
littl
effect
administ
oral
anoth
mek
inhibitor
also
known
shown
high
potenc
iav
vitro
complet
phase
ii
clinic
trial
antitumor
drug
applic
potenti
antiiav
drug
candid
recent
revisit
unlik
oral
bioavail
oral
administr
h
postinfect
protect
iavinfect
mice
oseltamivirtr
group
experienc
death
rate
oseltamivir
known
effect
administ
earli
stage
iav
infect
suggest
potenti
use
agent
use
iav
treatment
due
potenti
longer
therapeut
time
window
mainstay
antivir
formyl
peptid
receptor
locat
host
cell
surfac
identifi
erk
stimul
antagon
promot
surviv
iavinfect
mice
furthermor
antagonist
describ
possess
antivir
activ
iav
also
ibv
infect
promot
idea
antagon
suppress
rafmekerk
signal
cascad
could
potenti
novel
approach
treatment
broad
spectrum
influenza
virus
nuclear
export
vrnp
complex
host
cell
intracellular
transport
mechan
requir
deliv
vrnp
complex
host
plasma
membran
assembl
viral
rna
protein
final
stage
viral
replic
among
variou
vesicular
compart
found
cell
endosom
known
recycl
endocytos
membran
protein
lipid
plasma
membran
membran
homeostasi
properti
util
mani
rna
virus
includ
iav
iav
progeni
viru
product
found
significantli
reduc
knockdown
human
cell
line
furthermor
vrnp
complex
plasma
membran
transport
perturb
observ
knockdown
cell
cell
express
delet
mutant
famili
interact
protein
well
cell
treat
chemic
interfer
microtubul
direct
interact
vrnp
complex
also
verifi
demonstr
depend
vrna
complex
transport
vesicl
microtubul
network
viral
replic
sinc
protein
confer
mobil
properti
vesicl
molecular
motor
kinesin
requir
activ
transport
vesicl
cytoskeleton
famili
member
recent
identifi
molecular
motor
plasma
membran
transport
vrnpload
vesicl
knockdown
found
reduc
progeni
viru
product
overexpress
mutant
form
lack
motor
capac
result
disrupt
plasma
membran
distribut
vrnp
complex
later
stage
infect
data
suggest
apic
transport
viral
compon
via
could
potenti
serv
therapeut
target
iav
infect
examin
merit
tubulin
acetyl
deacetyl
affect
microtubul
stabil
histon
deacetylas
found
deacetyl
one
subunit
microtubul
studi
demonstr
involv
iav
replic
inhibit
tubacin
knockdown
gene
result
increas
progeni
viru
product
vrnp
complex
redistribut
toward
peripheri
infect
cell
addit
transport
ha
plasma
membran
viral
bud
also
found
inhibit
data
suggest
activ
stimul
could
potenti
approach
antiiav
therapi
despit
stimul
still
develop
sever
studi
suggest
iav
transmiss
cell
apic
membran
intercellular
connect
viru
bud
cell
membran
remain
major
rout
transmiss
virus
uninfect
cell
na
respons
cleavag
sialic
acid
prevent
interact
ha
host
cell
viral
bud
besid
viral
na
viral
ha
well
also
suggest
play
import
role
initi
bud
process
section
control
cholesterol
homeostasi
discuss
involv
host
cholesterol
viral
membran
fusion
viral
genom
releas
cytoplasm
recent
studi
demonstr
host
cholesterol
may
also
play
import
role
viral
bud
demonstr
overexpress
annexin
phospholipid
bind
protein
could
lead
decreas
cholesterol
level
within
golgi
apparatu
plasma
membran
ultim
caus
reduct
egress
progeni
virion
infect
cell
reduct
could
revers
addit
exogen
cholesterol
similar
overexpress
addit
hydrophob
polyamin
could
reduc
cholesterol
level
plasma
membr
ane
also
inhibit
viral
replic
sinc
iav
assum
bud
lipid
raft
cholesterolrich
plasma
membran
domain
demonstr
overexpress
treatment
could
hinder
progeni
viru
product
lower
cholesterol
content
plasma
membran
hypothesi
strengthen
recent
studi
resolv
cholesterolbind
site
viral
protein
suggest
iav
cluster
provid
membran
curvatur
scission
mediat
cholesterol
recent
report
util
two
differ
fdaapprov
cholesterollow
drug
gemfibrozil
lovastatin
state
reduct
stabil
infect
progeni
viru
compar
replic
within
cholesterolsuffici
host
cell
taken
togeth
data
suggest
control
cellular
cholesterol
content
would
effect
altern
drug
avail
repurpos
iav
treatment
vivo
work
need
confirm
hypothesi
gityp
gprotein
coupl
receptor
receptor
recent
identifi
key
host
factor
involv
iav
replic
apic
transport
viral
protein
ha
inhibit
low
intracellular
camp
level
stimul
signal
vitro
stimul
agonist
clonidin
inhibit
iav
replic
therapeut
administr
clonidin
reduc
pulmonari
edema
improv
surviv
rate
iavinfect
mice
develop
new
antivir
target
signal
seem
promis
deserv
investig
although
target
host
factor
viral
intervent
gener
provid
better
resist
barrier
emerg
resist
may
still
aris
therefor
combin
use
intervent
target
viru
host
factor
recommend
reduc
opportun
viral
develop
resist
one
exampl
would
combin
administr
na
inhibitor
oseltamivir
alongsid
antihost
factor
vatpas
inhibitor
diphyllin
ha
matur
inhibitor
nitazoxanid
antagonist
inhibitor
verdinexor
direct
assess
eas
emerg
escap
mutant
singl
combinatori
use
drug
requir
synergist
effect
combin
multidrug
approach
observ
thu
far
highli
suggest
increas
effect
singledrug
approach
tabl
summar
novel
host
target
regul
iav
replic
compar
rnai
small
molecular
chemic
remain
best
choic
drug
candid
due
fast
act
easytodeliv
properti
although
small
molecular
chemic
target
certain
host
factor
aforement
yet
develop
rnaiidentifi
involv
iav
replic
cycl
provid
lead
develop
new
iav
intervent
immun
system
aim
protect
host
infect
clear
pathogen
infect
occur
addit
complex
network
form
host
physiolog
immun
system
cooper
shape
diseas
outcom
modul
network
could
allevi
diseas
sever
iav
infect
immunolog
respons
elicit
iav
infect
review
detail
initi
stage
iav
infect
respiratori
epitheli
cell
primari
target
infect
infect
initi
recognit
infect
accomplish
via
detect
pathogenassoci
molecular
pattern
pamp
pattern
recognit
receptor
prr
see
tolllik
receptor
lead
express
secret
differ
cytokin
chemokin
tumor
necrosi
factor
tnf
well
type
iii
ifn
sentinel
cell
alveolar
macrophag
could
also
infect
induc
cytokin
main
sourc
type
ifn
type
ifn
known
induc
upregul
death
receptor
receptor
tnfrelat
apoptosisinduc
ligand
trail
lung
pneumocyt
produc
epitheli
cell
macrophag
act
chemoattract
neutrophil
monocyt
respect
neutrophil
one
earliest
immun
cell
recruit
site
infect
transmigr
neutrophil
carri
adhes
molecul
addit
antivir
activ
neutrophilreleas
reactiv
oxygen
speci
ro
defensin
pentraxin
uptak
iav
neutrophil
could
also
help
control
viral
propag
cell
support
replic
iav
besid
control
viral
replic
neutrophil
also
play
import
role
guid
migrat
iavspecif
tcell
infect
site
secret
leav
trail
infiltr
monocyt
howev
differenti
macrophag
dendrit
cell
dc
monocytesderiv
macrophag
report
permiss
host
iav
product
sustain
inflamm
produc
cytokin
magnitud
larger
resid
alveolar
macrophag
monocytederiv
dc
well
resid
airway
low
plasmacytoid
dc
pdc
two
type
convent
dc
low
hi
acquir
antigen
invad
pathogen
either
direct
infect
uptak
infect
dead
cell
presenc
type
ifn
dc
matur
encount
pamp
invad
pathogen
depend
subcellular
local
antigen
cytosol
endosom
antigen
load
onto
major
histocompat
complex
mhc
class
ii
molecul
respect
matur
dc
migrat
infect
site
drain
lymph
node
via
interact
antigen
present
via
mhc
class
ii
tcell
respect
interestingli
monocytesderiv
dc
engulf
infect
dead
cell
poor
antigen
present
tcell
requir
transfer
intact
mhc
class
ipeptid
complex
lymph
noderesid
dc
effici
antigenpres
cell
tcell
addit
antigen
present
pdc
well
known
high
abil
type
ifn
product
limit
viral
propag
within
lymph
node
tcell
activ
dc
differenti
clonal
expand
cytotox
tlymphocyt
ctl
aid
variou
cytokin
includ
type
ifn
help
activ
helper
cell
differenti
ctl
downregul
lymph
node
home
receptor
upregul
migrat
site
infect
within
site
infect
ctl
control
viral
replic
target
induc
apoptosi
virusinfect
cell
via
secret
perforin
granzym
well
ligat
death
receptor
infect
cell
tnf
fa
ligand
trail
hand
tcell
activ
present
mhc
class
ii
antigen
complex
dc
costimulatori
receptor
express
tcell
ligand
express
dc
play
import
role
activ
tcell
lead
differenti
differ
effector
cell
subset
includ
classic
recent
identifi
regulatori
cell
follicular
helper
cell
subset
cell
regul
differenti
ctl
mention
wherea
cell
contribut
activ
bcell
within
pregermin
center
lymph
node
follicular
helper
cell
interact
antigenprim
bcell
promot
prolifer
antigenprim
bcell
differenti
plasmablast
undergo
antibodi
classswitch
germin
center
detail
function
regulatori
cell
follicular
cell
cell
discuss
elsewher
plasmablast
enter
bloodstream
recruit
inflam
tissu
termin
differenti
plasma
b
cell
special
product
antibodi
pathogen
neutral
opson
antibodydepend
cellmedi
cytotox
etc
memori
tand
bcell
also
develop
matur
process
discuss
review
elsewher
schemat
diagram
show
summari
immun
respons
iav
infect
illustr
figur
yin
yang
theori
alway
use
describ
import
balanc
host
immun
respons
light
theori
treatment
strategi
aim
suppress
overwhelm
activ
host
immun
respons
revers
compens
unfavor
suppress
although
adapt
immun
respons
import
viral
clearanc
immedi
innat
immun
play
import
role
earli
control
infect
convers
major
factor
diseas
sever
due
immunopatholog
dysregul
immun
respons
caus
viral
infect
implic
sever
diseas
develop
acut
lung
injuri
ali
ali
sever
form
known
acut
respiratori
distress
syndrom
ard
report
preval
caus
mortal
iavinfect
patient
studi
suggest
iav
strain
could
associ
either
overactiv
human
infect
avian
suppress
immun
respons
recent
histori
seen
outbreak
iav
pandem
vari
sever
take
place
cost
million
live
one
exampl
would
deadli
spanish
flu
claim
live
million
million
peopl
infect
worldwid
patholog
examin
lung
section
mice
infect
reconstitut
iav
viru
reveal
necrot
bronchiol
sever
alveol
tissu
neutrophil
observ
predomin
inflammatori
cell
type
present
suggest
neutrophil
involv
pathogenesi
iav
infect
major
immun
cell
blood
circul
neutrophil
among
first
innat
immun
cell
recruit
site
infect
neutrophil
characterist
control
microbi
infect
gener
bactericid
neutrophil
extracellular
trap
net
consist
granul
protein
histon
decondens
chromatin
protect
destruct
role
neutrophil
iav
infect
describ
contrast
role
neutrophil
could
explain
factor
viral
strain
viral
dose
use
differ
experiment
setup
etc
protect
role
neutrophil
observ
mice
infect
low
nonleth
dose
iav
strain
display
neutrophilmedi
viral
clearanc
via
phagocytosi
deplet
neutrophil
found
enhanc
viral
load
iavinfect
anim
contrari
protect
natur
disput
due
associ
neutrophilgener
net
extens
net
format
observ
mice
infect
iav
strain
highli
pathogen
mice
histon
myeloperoxidas
within
net
induc
cell
death
lung
epithelium
endothelium
lead
loss
integr
alveolarcapillari
barrier
characterist
ali
yet
histon
shown
suppress
iav
replic
vitro
vivo
studi
demonstr
increas
lung
inflamm
damag
iavinfect
mice
treat
histon
interestingli
cotreat
lethal
infect
mice
antihiston
antibodi
oseltamivir
result
increas
anim
surviv
compar
infect
mice
group
treat
sole
oseltamivir
agreement
vitro
vivo
data
report
net
produc
cultur
neutrophil
patient
sever
infect
increas
alveolar
epitheli
cell
permeabl
lead
ali
importantli
plasma
net
level
posit
correl
diseas
sever
index
includ
higher
acut
physiolog
chronic
health
evalu
ii
score
multipl
organ
dysfunct
syndrom
demonstr
detriment
role
net
pathogenesi
sever
iav
infect
studi
demonstr
involv
superoxid
dismutas
myeloperoxidas
netosi
format
net
presenc
antimyeloperoxidas
antibodi
well
superoxid
dismutas
inhibitor
detc
significantli
reduc
netosi
final
tetrahydroisoquinolin
panpeptidylarginin
deiminas
pad
inhibitor
name
clamidin
suggest
inhibit
netosi
despit
report
iav
infect
knockout
mice
display
slight
improv
weight
loss
slight
prolong
endpoint
surviv
advantag
observ
compar
wt
mice
base
extens
find
present
target
net
prevent
ali
sever
case
iav
infect
includ
highli
pathogen
avian
iav
remain
promis
may
warrant
investig
innat
lymphoid
cell
cell
lymphoid
lineag
express
antigenspecif
bor
tcell
receptor
similar
thelper
cell
classifi
subset
abil
produc
type
type
type
cytokin
previou
studi
confirm
involv
ilc
group
linag
iav
infect
airway
inflamm
posit
side
recoveri
phase
iav
infect
express
amphiregulin
promot
airway
epithelium
repair
thu
facilit
recoveri
infect
lung
hand
respons
produc
macrophag
dc
nkt
cell
secret
induc
airway
hyperrespons
recruit
eosinophil
lung
also
mediat
airway
inflamm
sinc
eosinophilia
characterist
allerg
asthma
influenza
major
caus
morbid
mortal
asthma
patient
particular
interest
investig
role
iav
infect
particularli
asthma
patient
initi
describ
immatur
nk
cell
resid
liver
share
mani
phenotyp
similar
nk
cell
recent
appreci
tissueresid
previous
recogn
nk
cell
major
earli
sourc
antivir
primari
site
variou
viral
infect
includ
iav
interestingli
found
suppress
activ
reduc
product
exacerb
diseas
sever
influenza
infect
data
may
highlight
link
suggest
suppress
activ
via
product
iav
infect
ilc
final
identifi
function
cell
role
immun
respons
tumor
pathogen
infect
massiv
investig
recent
year
type
ifn
prostaglandin
corticosteroid
testosteron
report
suppress
activ
addit
epitheli
cytokin
thymic
stromal
lymphopoietin
well
lipid
mediat
prostaglandin
found
activ
therapeut
potenti
activ
suppressor
yet
deduc
studi
demonstr
involv
ilc
iav
infect
interplay
differ
ilc
subtyp
iav
infect
would
therefor
interest
area
explor
modul
ilc
activ
may
futur
approach
combat
iav
infect
reactiv
oxygen
speci
gener
special
enzym
nadph
oxidas
releas
iav
infect
nadph
oxidas
famili
consist
enzym
contain
differ
catalyt
subunit
name
dual
oxidas
duox
ro
report
display
benefici
limit
viral
replic
detriment
promot
ali
effect
cours
iav
infect
interestingli
protect
destruct
effect
ro
depend
enzym
ro
gener
dual
found
hostprotect
vitro
ro
gener
nuclear
duox
indirectli
regul
splice
iav
mrna
via
nuclear
speckleassoci
splice
complex
addit
alter
viral
mrna
splice
ro
gener
attribut
product
import
antiiav
ifn
respons
iav
infect
increas
viral
mrna
replic
observ
silenc
vitro
increas
viral
replic
also
observ
mice
doux
silenc
depict
protect
role
doux
iav
infect
unlik
doux
activ
could
harm
host
iav
infect
report
induc
endosom
ro
product
ro
could
target
conserv
tolllik
receptor
tlr
inhibit
type
ifn
express
mild
iav
infect
vivo
iavinfect
mice
treat
specif
inhibitor
cholestanolconjug
found
reduct
endosom
ro
product
restor
activ
display
decreas
viral
load
addit
ro
product
also
report
activ
mapkerk
signal
enhanc
export
vrnp
complex
thu
increas
viral
replic
see
target
raf
mekerk
pathway
knockdown
result
reduct
viral
replic
vitro
target
differ
nadph
oxidas
isoform
instead
scaveng
ro
consid
therapeut
approach
iav
infect
douxmedi
ro
product
benefici
harm
iav
infect
final
confus
iav
protein
demonstr
nox
inhibitor
could
inhibit
activ
studi
demonstr
suppress
iavinduc
significantli
inhibit
iav
viru
replic
besid
cholestanolconjug
aforement
apocynin
phagocyt
inhibitor
well
ro
scaveng
demonstr
amelior
hyper
upregul
cytokin
induc
iav
infect
vitro
reduc
peribronchi
inflamm
viral
titer
vivo
interestingli
ebselen
anoth
inhibitor
glutathion
peroxidas
mimet
could
reduc
inflammatori
statu
measur
bronchoalveolar
lavag
fluid
balf
mice
preexpos
cigarett
smoke
subsequ
infect
iav
taken
togeth
report
highlight
potenti
use
nadph
oxidas
inhibitor
ro
scaveng
treat
iav
infect
dysregul
cytokin
product
associ
elev
mortal
rate
observ
sever
iav
infect
immunomodul
cytokin
regard
promis
therapeut
tactic
recent
advanc
develop
approach
highlight
follow
section
tumor
necrosi
factor
two
main
function
viral
infectionit
activ
induc
express
cytokin
respons
host
immun
respons
induc
apoptosi
activ
signal
cascad
involv
tradd
fadd
caspas
tnf
known
highli
upregul
iavinfect
host
especi
host
infect
highli
pathogen
iav
howev
protect
counterprotect
function
associ
tnf
make
target
treatment
iav
protect
role
tnf
observ
infect
low
pathogen
iav
extrins
deriv
tnf
respons
attenu
tissuedamag
tcell
respons
addit
recruit
monocyt
cell
infect
site
tcell
respons
observ
deterior
lung
patholog
damag
healthi
noninfect
lung
epitheli
cell
upon
iav
infect
furthermor
tnf
defici
associ
increas
detect
balf
promot
surviv
prolifer
tcell
subsequ
tissu
damag
exacerb
lung
patholog
caus
upregul
monocyt
chemoattract
observ
tnf
mice
infect
subleth
dose
iav
addit
decreas
tcell
contract
due
enhanc
express
antiapoptot
protein
observ
subleth
iavinfect
tnfdefici
mice
compar
wt
mice
whole
substanti
evid
support
protect
role
tnf
iav
infect
hand
correl
tnf
pulmonari
edema
welldocu
tnf
observ
stimul
express
alveolar
epitheli
cell
transgen
mice
model
resembl
extens
iav
infect
lung
tissu
caus
alveolar
damag
lung
edema
hemorrhag
addit
lung
edema
tnf
also
report
correl
iavassoci
encephalopathi
howev
notabl
despit
iavassoci
encephalopathi
direct
invas
central
nervou
system
rare
suggest
iavassoci
encephalopathi
could
instead
result
peripher
infect
furthermor
tnf
shown
increas
permeabl
bloodbrain
barrier
bbb
contribut
neural
damag
studi
support
antitnf
approach
potenti
therapi
sever
iav
infect
present
etanercept
antitnf
drug
administ
treatment
rheumatoid
arthriti
tnf
inhibitor
even
tnf
direct
treatment
test
iav
treatment
etanercept
shown
protect
vivo
lethal
infect
mice
highli
virul
mouseadapt
iav
strain
observ
made
increas
surviv
rate
decreas
morbid
express
proinflammatori
cytokin
lung
injuri
edema
protect
role
demonstr
mice
challeng
subleth
iav
infect
mice
display
exacerb
pulmonari
damag
lung
injuri
due
observ
declin
surviv
alveolar
type
ii
cell
alveolar
epitheli
cell
iav
suppress
antiapoptot
bclxl
express
caus
cell
death
neutrophil
critic
viral
clearanc
addit
restor
express
bclxl
vitro
consid
underli
mechan
observ
surviv
advantag
wt
mice
knockout
mice
mild
iav
infect
also
shown
induc
prolifer
lung
regulatori
cell
act
limit
excess
prolifer
tcell
subsequ
inflict
damag
would
henc
prevent
tissu
damag
observ
lung
immunopatholog
despit
appar
protect
role
high
level
serum
cerebrospin
fluid
report
sever
neurolog
complic
iav
case
use
marker
prognosi
role
regul
bbb
permeabl
report
potenti
detriment
neurolog
complic
suppress
hyperinduc
form
therapi
sever
iav
infect
consid
one
option
antibodybas
drug
tocilizumab
current
administ
clinic
treatment
rheumatoid
arthriti
howev
studi
usag
drug
treat
hyper
upregul
due
sever
iav
infect
yet
conduct
hand
case
virusinduc
ard
use
extracorpor
cytokin
hemoadsorpt
devic
remov
cytokin
includ
tnf
bloodstream
show
benefici
patient
research
requir
confirm
whether
remov
neutral
could
potenti
therapi
sever
iav
infect
activ
tcell
crucial
viral
clearanc
howev
tightli
regul
limit
tcell
inflict
host
cell
damag
mediat
induct
act
suppress
tcell
reduc
morbid
regulatori
tcell
much
like
immunomodulatori
approach
time
appli
care
assess
compar
placebotr
iavinfect
group
earli
administr
iavinfect
mice
fact
led
poorer
viral
clearanc
increas
morbid
deterior
lung
histopatholog
administr
recoveri
phase
day
postinfect
acceler
recoveri
improv
lung
immunopatholog
notabl
could
also
suppress
respons
increas
suscept
secondari
aureu
infect
therefor
coadministr
antibiot
consid
util
potenti
iav
treatment
type
iii
ifn
antivir
properti
virus
counteract
ifn
gain
advantag
propag
iav
viral
protein
inhibit
product
ifn
antagon
key
transcript
factor
ifn
prevent
process
cellular
premrna
includ
ifn
directli
interact
retino
acidinduc
gene
rig
receptor
critic
innat
sens
suppress
ifn
product
infect
addit
inhibit
ifn
express
induct
inhibit
ifn
signal
suppress
cytokin
signal
document
recognit
triphosph
viral
rna
rigi
receptor
shown
induc
express
turn
repress
type
ifn
express
due
ifn
key
contributor
antivir
immun
respons
impair
type
iii
ifn
product
may
caus
escal
otherwis
mildli
pathogen
iav
infect
lifethreaten
one
type
ifn
demonstr
inhibit
iav
replic
vitro
vivo
administr
type
ifn
anim
model
display
effect
prophylact
capac
lower
viral
titer
detect
nasal
wash
test
anim
howev
host
suscept
iav
infect
remain
unchang
notabl
protect
effect
confer
optim
dose
type
ifn
low
moder
amount
unit
per
mice
daili
higher
dosag
unit
per
mice
daili
shown
increas
morbid
addit
clinic
trial
demonstr
prophylac
tic
administr
type
ifn
reduc
diseas
sever
lower
suscept
iav
male
particip
age
despit
rel
success
result
seen
prophylact
use
ifn
therapeut
use
greater
clinic
relev
mice
treat
type
ifn
postiav
infect
show
success
reduct
lung
iav
titer
display
increas
morbid
mortal
comparison
vehicletr
mice
possibl
explan
phenomenon
induct
excess
inflammatori
respons
epitheli
cell
death
type
ifn
account
observ
lung
patholog
iavinfect
anim
treat
type
ifn
addit
downregul
tcell
type
ifn
correl
increas
suscept
secondari
pneumonia
infect
argu
potenti
use
type
ifn
treatment
iav
infect
comparison
type
ifn
administr
type
iii
ifn
may
provid
advantag
control
iav
replic
without
risk
previous
report
type
ifnsmedi
immunopatholog
sideeffect
howev
recent
studi
aim
stimul
ifn
signal
systemat
administr
rigi
ligand
postiav
infect
demonstr
type
type
iii
ifn
signal
import
confer
protect
fatal
iav
infect
vivo
though
studi
measur
product
type
iii
ifn
well
chang
viral
load
respect
ifnar
ifnlr
knockout
addit
human
immun
cell
primari
target
iav
infect
could
suscept
iav
becom
effici
host
cell
viru
replic
report
possess
subpar
respons
type
iii
ifn
lead
preliminari
conclus
sole
use
type
iii
ifn
treatment
may
feasibl
report
suggest
use
type
iii
ifn
type
ifn
frontlin
therapeut
agent
counter
iav
infect
may
requir
investig
inhibit
select
inhibitor
nimesulid
celecoxib
previous
demonstr
suppress
hyper
upregul
proinflammatori
cytokin
induc
highli
pathogen
avian
iav
addit
use
zanamivir
tandem
specif
inhibitor
shown
increas
surviv
rate
mice
lethal
infect
avian
iav
compar
mice
treat
sole
zanamivir
activ
regul
downstream
prostaglandin
product
one
exampl
major
type
prostaglandin
recent
demonstr
play
import
role
iav
infect
significantli
upregul
respons
iav
infect
lead
inhibit
antivir
type
ifn
product
macrophag
subsequ
increas
viru
replic
use
chemic
antagon
downstream
signal
molecul
respect
shown
induc
antivir
type
ifn
product
vivo
treatment
mice
lethal
challeng
iav
antagonist
significantli
improv
surviv
rate
recent
studi
demonstr
abil
modifi
tcm
decoct
reduc
product
subsequ
morbid
mice
lethal
challeng
iav
improv
lung
patholog
observ
long
histori
clinic
tcm
use
support
clinic
feasibl
inhibit
option
treat
sever
iav
infect
pattern
recognit
receptor
host
cell
sens
specif
pamp
present
viral
surfac
gener
replic
prr
broadli
divid
two
class
function
locat
defin
locat
prr
classifi
groupsmembranebound
tlr
ctype
lectin
receptor
cytosol
rigilik
nodlik
receptor
secret
collectin
pentraxin
signific
research
conduct
prr
regard
iav
infect
tlr
rigi
receptor
extens
studi
major
role
elicit
host
immun
respons
cytokin
ifn
express
iav
infect
rigi
receptor
investig
function
relev
iav
infect
target
receptor
form
iav
treatment
extens
review
section
cover
recent
research
tlr
target
differ
tlr
treat
iav
infect
human
identifi
express
mice
identifi
express
function
well
tlrswith
except
adaptor
protein
signal
transduct
util
trif
adaptor
known
abil
util
either
trif
choic
adaptor
depend
subcellular
locat
differ
tlr
well
recent
reveal
play
role
orchestr
host
immun
respons
contribut
iav
pathogenesi
except
tlr
activ
larg
caus
releas
proinflammatori
cytokin
hypercytokinemia
lead
ali
major
caus
mortal
sever
iav
infect
addit
dysregul
cytokin
releas
excess
product
ro
associ
ali
develop
fact
lung
injuri
sever
pulmonari
infect
iav
sar
could
caus
oxid
stress
iav
infect
activ
nadph
oxidas
subsequ
produc
oxid
papc
endogen
phospholipid
oxid
papc
serv
agonist
activ
signal
cascad
eventu
trigger
releas
ultim
induc
onset
ali
addit
oxid
papc
induct
endogen
protein
upon
intracellular
prr
recognit
iav
subsequ
induc
activ
contribut
iavinduc
mortal
sinc
proven
import
ali
induct
henc
iavrel
mortal
manipul
stimul
antagon
could
potenti
reduc
sever
iav
infect
eritoran
specif
antagonist
initi
purpos
treatment
sepsi
fail
phase
iii
clinic
trial
due
improv
patient
care
placebo
group
prevent
eventu
use
sepsi
treatment
vivo
administr
eritoran
mice
lethal
infect
iav
result
improv
clinic
score
lung
patholog
result
reduc
viral
titer
delay
administr
eritoran
day
infect
beyond
recommend
therapeut
time
window
within
h
first
display
clinic
symptom
use
oseltamivir
also
demonstr
signific
benefit
infect
mice
compar
nontreat
group
suggest
prolong
therapeut
time
window
iav
treatment
compar
mainstay
antivir
drug
treatment
newer
structur
simpler
specif
antagonist
alongsid
newli
develop
decoy
peptid
shown
disrupt
signal
via
tirap
shown
protect
mice
lethal
iav
infect
result
support
potenti
use
antagon
mean
treat
sever
iav
infect
suppress
tlr
signal
pathwayssuch
block
signal
use
antibodi
significantli
protect
lethal
administ
day
postiav
infect
studi
also
demonstr
knockout
mice
better
surviv
wildtyp
mice
evid
significantli
faster
regain
bodi
weight
postinfect
lower
viral
titer
lung
fewer
patholog
chang
lung
increas
number
tlr
antagonist
develop
alongsid
sever
agent
also
shown
effect
tlr
polysaccharid
isol
r
isatidi
tradit
chines
medicin
herb
use
treat
iav
infect
recent
shown
inhibit
proinflammatori
cytokin
vitro
downregul
upstream
express
menk
endogen
protein
express
adren
medulla
shown
prophylact
therapeut
increas
surviv
rate
reduc
viralcaus
lung
patholog
viral
titer
mice
lethal
challeng
iav
determin
caus
downregul
result
suggest
potenti
downregul
tlr
express
treatment
iav
infect
abovement
data
suggest
modul
tlr
signal
express
promis
approach
treat
sever
influenza
diseas
deserv
immedi
investig
tabl
summar
new
immunomodulatori
approach
combat
iav
infect
well
document
patient
diabet
mellitu
greater
tendenc
develop
sever
iav
infect
healthi
patient
hyperglycemia
increas
suscept
host
iav
infect
via
viral
uptak
promot
vatpas
assembl
immunosuppress
addit
virus
reli
host
metabol
perform
essenti
function
replic
process
exert
larg
energi
demand
host
within
short
period
time
energi
suppli
depend
host
metabol
iav
virus
report
modifi
metabol
state
host
exampl
increas
cmycdepend
glycolysi
glutaminolysi
demonstr
infect
cell
chang
glucos
glutamin
metabol
revers
upon
addit
inhibit
iavmedi
cmyc
induct
administr
day
prior
infect
day
postinfect
shown
decreas
lung
viral
titer
improv
surviv
rate
iavinfect
mice
small
molecul
clotrimazol
target
lipid
metabol
also
demonstr
suppress
iav
replic
vitro
addit
import
gener
energi
biosynthesi
recent
research
demonstr
cellular
metabol
affect
immun
cell
function
dysregul
immun
respons
observ
mani
diseas
associ
specif
metabol
configur
virus
influenza
inclus
found
induc
drastic
alter
metabol
level
program
macrophag
infect
host
observ
mark
differ
kreb
cycl
key
metabol
pathway
signific
due
role
macrophag
immun
cell
critic
pathogenesi
mani
inflammatori
diseas
activ
macrophag
succin
kreb
cycl
intermedi
found
possess
inflammatori
signal
accumul
succin
gener
ro
lead
subsequ
activ
hypoxiainduc
factor
induct
cytokin
recent
studi
identifi
abil
itacon
anoth
kreb
cyclederiv
metabolit
block
product
inflammatori
factor
prevent
inflamm
protect
mice
lethal
level
inflamm
occur
infect
data
suggest
critic
role
kreb
cycl
intermedi
regul
cytokin
profil
inflamm
metabolit
gener
innat
immun
cell
distinct
configur
could
differ
role
beyond
bioenerget
function
signal
regul
transcript
orchestr
innat
immun
respons
despit
lack
research
conduct
thu
far
applic
immunometabol
approach
influenza
treatment
prospect
manipul
immun
respons
modul
immun
cell
metabol
state
promis
research
focu
identif
metabolit
modul
immun
cell
function
substanti
improv
therapeut
strategi
treat
iav
diseas
latest
advanc
highthroughput
technolog
eg
meta
bolom
use
approach
systemat
investig
chang
metabol
mechan
iav
infect
identif
import
metabolit
involv
iav
infect
new
approach
modul
host
metabol
intervent
multipl
hostbas
intervent
strategi
influenza
develop
develop
approach
target
host
machineri
requir
viru
replic
seem
promis
thu
far
addit
research
need
determin
effect
modul
host
immun
respons
influenza
treatment
increasingli
import
sinc
target
host
factor
may
play
distinct
role
respons
infect
differ
influenza
viral
strain
make
manag
influenza
sole
target
singl
specif
host
factor
difficult
hostbas
intervent
offer
obviou
advantag
convent
antivir
higher
barrier
drug
resist
due
greater
genet
stabil
host
factor
mutationpron
natur
viral
compon
addit
administr
feasibl
key
factor
consid
usag
drug
mainstay
antivir
iav
infect
na
inhibitor
blocker
recommend
administ
within
h
symptom
onset
optim
antivir
activ
short
treatment
window
may
fulli
fulfil
clinic
set
novel
hostbas
intervent
report
therapeut
time
window
longer
convent
timefram
even
day
postinfect
provid
clear
clinic
advantag
na
inhibitor
blocker
addit
hypercytokinemia
ard
could
contribut
diseas
sever
mortal
instanc
sever
influenza
infect
virustarget
antivir
provid
littl
allevi
complic
sinc
host
immun
respons
indispens
host
defens
invad
pathogen
use
immunemodul
suppress
detriment
effect
retain
benefici
protect
host
remain
challeng
time
dosag
medic
administr
would
critic
determin
drug
effect
influenza
treatment
target
virusinduc
metabol
chang
restor
host
normal
metabol
may
new
direct
combat
influenza
diseas
research
immunometabol
field
along
side
studi
modul
immun
respons
infecti
diseas
alter
host
metabol
process
would
creat
new
direct
futur
research
expect
yield
signific
discoveri
may
provid
new
therapeut
option
treatment
iav
infect
smyl
conceptu
work
il
asm
draft
review
section
tfi
smyl
wrote
manuscript
